Leflunomide Tablet
Product Images NDC 23155-043

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 23155-043). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural-formula (Structural Formula)

Chemical structure of leflunomide, showing its molecular framework including a trifluoromethyl-substituted phenyl ring and an isoxazole moiety linked via a carbamoyl group.*

FDA Label Image

Teriflunomide-structural-formula. (Teriflunomide Structural Formula)

Chemical structure of teriflunomide, associated with leflunomide, showing atoms and bonds including a trifluoromethyl-substituted aromatic ring and cyano group. The structure is labeled A77 1726 (teriflunomide).*

FDA Label Image

Figure-1 (Figure 1)

Bar chart showing the percentage of ACR 20 responders at endpoint across three clinical trials over different durations (12 months, 6 months). The chart compares response rates between Leflunomide, Methotrexate, Placebo, and Sulfasalazine groups, with Leflunomide showing variable responder percentages in each trial.*

FDA Label Image

Figure-2 (Figure 2)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over a 12-month period for three groups labeled PL, MTX, and LEF. The x-axis represents months (0, 3, 6, 9, 12), and the y-axis shows percent responders from -10 to 70%. LEF group shows the highest response rates consistently over time.*

FDA Label Image

Figure-3 (Figure 3)

A bar chart titled 'Change in Sharp Score' showing disease progression over three trials at different durations: Trial 1 (12 months), Trial 2 (6 months), and Trial 3 (12 months). The x-axis labels treatments: Leflunomide (L), Methotrexate (M), Sulfasalazine (S), and Placebo (P). The y-axis represents Sharp Score progression with bars displaying numerical values indicating changes for each treatment in the respective trials.*

FDA Label Image

Figure-4 (Figure 4)

A bar chart titled 'Change in Functional Ability Measure' showing improvement measured by the HAQ Disability Index across three trials at 6 or 12 months. The chart compares leflunomide (L), methotrexate (M), placebo (P), and sulfasalazine (S) groups, with improvements indicated by negative values in the bars.*

FDA Label Image

Avet-logo (Avet Logo)

FDA Label Image

Label-10mg (Label 10mg)

Leflunomide Tablets, USP 10 mg oral tablets in a carton with 30 tablets. The label includes dosage strength, quantity, and warnings about storage and handling. The product is labeled for prescription use only and distributed by Avet Pharmaceuticals Inc. The package features barcodes and regulatory information.*

FDA Label Image

Label-20mg (Label 20mg)

Leflunomide Tablets USP 20 mg oral tablet carton label. The label indicates 30 tablets per package, by Avet Pharma, a division of Heritage Pharmaceuticals Inc. It includes dosage information, storage instructions, and barcode on the side. The design features blue and red text on a white background with the Avet Pharma logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.